Trial
NCT03768531
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Bristol-Myers Squibb
Condition
Resectable Biliary Tract Cancer
Intervention
Nivolumab
Why stopped
No subjects were enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-13